Figure 1.
![Figure 1. Five-year survival probability on pooled meta-analysis. The analysis accounts for 7843 patients in whom CLL-IPI was applied at different points in the course of their disease (ie, at diagnosis [8 series] and time of first treatment [3 series]). SCAN, SCALE Scandinavian population-based case-control study.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/3/10.1182_blood-2017-09-806034/4/blood806034f1.jpeg?Expires=1723267243&Signature=xFBEj2zrSa3eXRkdKV7wIPyxQBsND~81-c0lEVE3LURwNBSaLkC9VrmqhHYZdhNByQ1T0pFHDKZG~oYrhMddTIv5qm0QidJGdmam8VLwVQ2LVjqiv--qP37sKLX0D8o7wHtm5iYDyqhNNuZxIZQ7r5qeQBu9vARZpU~uXhPJLfd7hrMGs-~DrLHF4GTFPN9lPdP6sc3bijmFFKWKGRd41bID-v1h71s6GPnz09NGHdHl3NXEUcBB34Hek0xK38tAI3AN8nsz6Q6PV6SrE4LU1fj9KULfVgZxrYkOIdcnWrYA2t55gfWDW47gGuDmUONLCkhOpyQeNzcHW9n8TMie4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Five-year survival probability on pooled meta-analysis. The analysis accounts for 7843 patients in whom CLL-IPI was applied at different points in the course of their disease (ie, at diagnosis [8 series] and time of first treatment [3 series]). SCAN, SCALE Scandinavian population-based case-control study.
